ianalumab
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Pressure score
40
Momentum score
20
Why This Matters
Merck is a direct competitive threat because it has a Phase III program in Hematology · Immune Thrombocytopenia (ianalumab) and could narrow Novartis's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Phase III
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Late-stage competitor could compress launch window and payer leverage before approval.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Merck's ianalumab directly references the same indication focus (Hematology · Immune Thrombocytopenia) as this signal.
Source: Merck
View source documentRelated Signal
Novartis initiates tolerability study of ianalumab with TPO-RA in ITP patients
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 2
Roche
3 competitive findings
Top program: ianalumab
- Pressure
- 81
- Momentum
- 51
- Threat
- regulatory competitor
- Stage
- Approved
81RocheHighianalumab·Approved
Merck
1 competitive finding
Top program: ianalumab
- Pressure
- 40
- Momentum
- 20
- Threat
- direct competitor
- Stage
- Phase III
40MerckMediumianalumab·Phase III